Publicaciones en colaboración con investigadores/as de VU University Medical Center (13)

2019

  1. Insights on Multiple Myeloma Treatment Strategies

    HemaSphere, Vol. 3, Núm. 1

2018

  1. Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European Expert Panel

    Journal of Hematology and Oncology, Vol. 11, Núm. 1

  2. Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network

    Leukemia, Vol. 32, Núm. 7, pp. 1542-1560

2017

  1. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 28, pp. iv52-iv61

  2. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study

    Leukemia, Vol. 31, Núm. 11, pp. 2443-2448

  3. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the European myeloma network

    Leukemia, Vol. 2017

  4. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

    The Lancet Oncology, Vol. 18, Núm. 4, pp. e206-e217

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2014

  1. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

    American Journal of Hematology, Vol. 89, Núm. 4, pp. 355-362

  2. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

    The Lancet Oncology, Vol. 15, Núm. 12, pp. e538-e548

2011

  1. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: Consensus statement

    Leukemia, Vol. 25, Núm. 5, pp. 749-760

  2. Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)

    Blood, Vol. 118, Núm. 17, pp. 4519-4529

2010

  1. Current multiple myeloma treatment strategies with novel agents: A European perspective

    Oncologist, Vol. 15, Núm. 1, pp. 6-25